A highly anticipated clinical trial was just published by the prestigious Journal of Nutrition with a surprising finding: that C15:0, a trace dietary saturated fat present in butter, can lower liver enzymes in young adults susceptible to fatty liver disease. Nonalcoholic fatty liver disease (NAFLD), also

On July 26, 2024, the 11th Aging Research and Drug Discovery meeting had to stop registrations after reaching full capacity. It sold out two weeks faster than in 2023, a month prior to the start of the conference. The conference is a non-profit volunteer-run event organized

Today, Rejuve.AI, the world’s first decentralized AI longevity research network, has announced four new partnerships, bringing the grand total to 20 organizations that have committed alongside Rejuve.AI to help humankind live longer. Rejuve.AI is working to lengthen lifespans by paying members in its RJV crypto token

Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions. The agreement, potentially exceeding $300 million in value for the first of

Ora Biomedical, Inc. announces it has been selected by AFWERX for a SBIR Phase I contract in the amount of $75,000 focused on developing novel therapeutics to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and

A debate titled “How to Defeat Aging” will be held on May 27, 2024, featuring two distinguished scientists, Peter Fedichev and Aubrey de Grey, both proponents of radical life extension with biotechnology, with opposing views. Fedichev believes aging is irreversible but can be slowed or stopped,

John Hancock, along with its Toronto-based parent company Manulife (NYSE:MFC), today announced a five-year, multimillion-dollar research collaboration with the Massachusetts Institute of Technology (MIT) AgeLab, a multi-disciplinary research institute that works with business, government, and NGOs, leading innovation and research to help improve the quality of

LongX, an initiative dedicated to providing early-career avenues into longevity, announced a call for applications for its 2024 Xplore Program. The program lasts from June 2024 until September 2024 and features a one-month longevity primer course followed by the opportunity to gain educational experience with a

Berlin’s event landscape is growing: Longevity Week will take place in the German capital for the first time from May 6-12, 2024. The opening event will take place on May 6th at the Langenbeck-Virchow-Haus in Berlin Mitte near the Charité hospital. A total of 15 events

SynBioBeta, the leading community of entrepreneurs, investors, innovators, and biological engineers, today announced details for its flagship SynBioBeta 2024 conference. The premier annual event for the synthetic biology industry will be held May 6-9, 2024, in San Jose, gathering an estimated 2,000 attendees from around the

As the conference season kicks off, VC investors are gearing up for a cautiously optimistic 2024, where the normalization of valuations stands out as a positive trend. However, a growing concern shows over the potential impact of geopolitical conflicts and climate change pressures on this year’s

Following the resounding success of the Longevity Investors Lunch held during the World Economic Forum in Davos in January, Longevity Investors is thrilled to unveil the upcoming Longevity Investors Conference 2024. Set against the picturesque backdrop of Gstaad, Switzerland, the conference is scheduled to take place

Hevolution announced its investment of $20 million (SAR 75,000,000) as the lead investor for a $50 million (SAR 188,000,000) Series A financing extension in Aeovian Pharmaceuticals. Hevolution’s investment will advance promising therapies that target the mTORC1 biological pathway, helping find solutions to major unmet medical needs